Neoadjuvant chemoimmunotherapy cycle number selection for non-small cell lung cancer and clinical outcomes: a real-world analysis.

MLA

Zhang, Baihua, et al. “Neoadjuvant Chemoimmunotherapy Cycle Number Selection for Non-Small Cell Lung Cancer and Clinical Outcomes: A Real-World Analysis.” Frontiers in Oncology, vol. 13, Sept. 2023, p. 1200625. EBSCOhost, https://doi.org/10.3389/fonc.2023.1200625.

APA

Zhang, B., Guo, X., Jia, R., Wang, Z., Wu, J., Chen, X., Li, J., Yang, D., Li, X., Wang, W., & Xiao, Q. (2023). Neoadjuvant chemoimmunotherapy cycle number selection for non-small cell lung cancer and clinical outcomes: a real-world analysis. Frontiers in Oncology, 13, 1200625. https://doi.org/10.3389/fonc.2023.1200625

Chicago

Zhang, Baihua, Xiaotong Guo, Ran Jia, Zhan Wang, Jie Wu, Xiaoyan Chen, Jigang Li, et al. 2023. “Neoadjuvant Chemoimmunotherapy Cycle Number Selection for Non-Small Cell Lung Cancer and Clinical Outcomes: A Real-World Analysis.” Frontiers in Oncology 13 (September): 1200625. doi:10.3389/fonc.2023.1200625.